Clinical Trial

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-06; most recent amendment 2024-11-18.
Status change: Not Yet Recruiting → Recruiting 2024-11-18
Trial Details
NCT Number NCT06452706
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Breast Cancer
Enrollment 42 participants
Start Date 2024-11-14
Primary Completion 2026-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2024-11-19